Colorectal cancer (CRC) stands as the second most common cause of cancer-related mortality globally and p53, a widely recognized tumor suppressor, contributes to the development of CRC.

Journal of Nuclear Medicine September 2024, jnumed.124.267736; DOI: https://doi.org/10.2967/jnumed.124.267736 ...

The findings were recently published in Communications Chemistry. p53 is central to the body's defense against cancer, tasked ...

While a study suggests that spike proteins found in the COVID-19 vaccine can affect a tumor suppressor gene, it is not proof ...

Accumulation of mutant p53 may augment colorectal cancer stem cells (CCSCs) phenotype and enhance colorectal tumorigenesis. Thus, reducing the level of mutant p53 protein is an attractive anticancer ...

They state, "In lung cancer p53 mutations have been found in 56% of tissue samples, and in colorectal, esophageal, ovarian, pancreatic, and skin cancers, prevalences of 44-50% have been reported." ...

We also demonstrated that, in vivo when the ligand-liposome encapsulated wt p53 was injected I.V., preexisting SCCHN and prostate cancer xenografts completely regressed after radiotherapy.

Researchers from the University of Michigan Rogel Cancer Center have uncovered a promising new target in the battle against ...

This important study reports, with convincing evidence, that a long non-coding RNA disrupts the activity of the tumor suppressor p53 to contribute to the growth and therapeutic response of ...

Most uterine cancers have excellent five-year survival rates—up to 95% for localized cancer. Serous uterine cancer is an ...

Discover the potential of chronotherapy, a groundbreaking approach to cancer treatment that aligns chemotherapy with your ...